- Home
- SIEB vs IPHA Comparison
SIEB vs IPHA Comparison
Compare SIEB & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIEB
- IPHA
- Stock Information
- Founded
- SIEB 1886
- IPHA 1999
- Country
- SIEB United States
- IPHA France
- Employees
- SIEB N/A
- IPHA N/A
- Industry
- SIEB Investment Bankers/Brokers/Service
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SIEB Finance
- IPHA Health Care
- Exchange
- SIEB Nasdaq
- IPHA Nasdaq
- Market Cap
- SIEB 148.8M
- IPHA 160.1M
- IPO Year
- SIEB N/A
- IPHA 2019
- Fundamental
- Price
- SIEB $4.21
- IPHA $1.83
- Analyst Decision
- SIEB
- IPHA Strong Buy
- Analyst Count
- SIEB 0
- IPHA 1
- Target Price
- SIEB N/A
- IPHA $11.00
- AVG Volume (30 Days)
- SIEB 180.4K
- IPHA 9.9K
- Earning Date
- SIEB 08-13-2025
- IPHA 03-27-2025
- Dividend Yield
- SIEB N/A
- IPHA N/A
- EPS Growth
- SIEB 117.05
- IPHA N/A
- EPS
- SIEB 0.46
- IPHA N/A
- Revenue
- SIEB $92,064,000.00
- IPHA $20,831,349.00
- Revenue This Year
- SIEB N/A
- IPHA $209.83
- Revenue Next Year
- SIEB N/A
- IPHA $83.15
- P/E Ratio
- SIEB $10.13
- IPHA N/A
- Revenue Growth
- SIEB 21.82
- IPHA N/A
- 52 Week Low
- SIEB $1.41
- IPHA $1.29
- 52 Week High
- SIEB $5.77
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SIEB 39.36
- IPHA 33.33
- Support Level
- SIEB $4.34
- IPHA $1.82
- Resistance Level
- SIEB $4.71
- IPHA $2.21
- Average True Range (ATR)
- SIEB 0.34
- IPHA 0.07
- MACD
- SIEB -0.16
- IPHA -0.03
- Stochastic Oscillator
- SIEB 4.88
- IPHA 6.74
About SIEB Siebert Financial Corp.
Siebert Financial Corp is a diversified financial services firm and provides a full range of brokerage and financial advisory services including securities brokerage, investment advisory and insurance offerings, and corporate stock plan administration solutions. The firm mainly provides online and traditional brokerage and related services to retail investors and also acts as an investment advisor for its subsidiary. The company operates in the securities brokerage and asset management industry. It also engages in Insurance services, Robo-advisory technology, and Prime brokerage business through its subsidiaries.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.